

Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)

<https://marketpublishers.com/r/S8A9375EE78EN.html>

Date: November 2018

Pages: 0

Price: US\$ 2,190.00 (Single User License)

ID: S8A9375EE78EN

Abstracts

Spinal muscular atrophy is a disease that causes muscle weakness which mostly appears in newborn children. Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally. Spinal muscular atrophy is basically 4 types – Type 1, Type 2, Type 3 and type 4. Most patients suffers with Spinal muscular atrophy type 1. According to Renub Research Global Spinal Muscular Atrophy (SMA) market is anticipated to grow at a CAGR of 14.29 percent in future. This double digit growth rate will happen due to expected launch of new drugs, better reimbursement options and decline in drugs prices.

Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of new born children in which patients are not in position to sit in their lifetime and normally they die within 6 months. In spinal muscular atrophy type 2, patients can sit but cannot walk. Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during the adulthood.

Renub Research report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies

(Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years

At present only Biogen’s Spinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc. Other companies are also working for new drugs development and they hope to enter in the market place very soon as their drugs are in Phase III clinical trials.

By Country - Market Segmentation

Spinal muscular atrophy market by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is a leading market place due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure.

By Total & Treated Patients - Population Segmentation

Spinal muscular atrophy Total & Treated Patients by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is dominating in the treated SMA patients globally.

By Drugs - Market Segmentation

The report by Renub Research studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales.

The Report has been analyzed from 9 Major Viewpoints

1. Global Spinal Muscular Atrophy Market (Present & Forecast)
2. Global Spinal Muscular Atrophy Market Share, Patients Share, Treated Patients Share (Present & Forecast)
3. Country Spinal Muscular Atrophy Market (Present & Forecast)
4. Country Spinal Muscular Atrophy Patients Population (Present & Forecast)
5. Country Spinal Muscular Atrophy Treated Patients Population (Present & Forecast)

6. Spinal Muscular Atrophy Drugs Sales (Present & Forecast)
7. Global – Clinical Study on Spinal Muscular Atrophy & Drugs Pipeline
8. Growth Drivers and Challenges
9. Key Spinal Muscular Atrophy Companies Initiatives and Financial Insight

Country Covered in this Report

United States

United Kingdom

France

Germany

Italy

Spain

Japan

Drugs Details Covered in this Report

Spinraza

AVXS-101

CK2127107

RG7916

Olesoxime

LMI070

Company Covered in this Report

Biogen Inc.

Roche AG

Novartis AG

Cytokinetics Inc

Contents

1. INTRODUCTION

- 1.1 Market Definition
- 1.2 Currency Conversion

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. GLOBAL SPINAL MUSCULAR ATROPHY MARKET AND PATIENTS ANALYSIS

- 4.1 Spinal Muscular Atrophy Market
- 4.2 Spinal Muscular Atrophy Patient Numbers
- 4.3 Spinal Muscular Atrophy Treated Patient Number

5. SHARE ANALYSIS – GLOBAL SPINAL MUSCULAR ATROPHY

- 5.1 Country Market Share
- 5.2 Patients Population Share
- 5.3 Treated Patients Share

6. UNITED STATES

- 6.1 Spinal Muscular Atrophy Market
- 6.2 Spinal Muscular Atrophy Patient Numbers
- 6.3 Spinal Muscular Atrophy Treated Patients

7. UNITED KINGDOM

- 7.1 Spinal Muscular Atrophy Market
- 7.2 Spinal Muscular Atrophy Patient Numbers
- 7.3 Spinal Muscular Atrophy Treated Patient Numbers

8. GERMANY

- 8.1 Spinal Muscular Atrophy Market
- 8.2 Spinal Muscular Atrophy Patient Numbers

8.3 Spinal Muscular Atrophy Treated Patients

9. ITALY – SPINAL MUSCULAR ATROPHY

9.1 Spinal Muscular Atrophy Market

9.2 Spinal Muscular Atrophy Patient Numbers

9.3 Spinal Muscular Atrophy Treated Patient Numbers

10. FRANCE – SPINAL MUSCULAR ATROPHY

10.1 Spinal Muscular Atrophy Market

10.2 Spinal Muscular Atrophy Patient Numbers

10.3 Spinal Muscular Atrophy Treated Patient Numbers

11. SPAIN

11.1 Spinal Muscular Atrophy Market

11.2 Spinal Muscular Atrophy Patient Numbers

11.3 Spinal Muscular Atrophy Treated Patient Numbers

12. JAPAN

12.1 Spinal Muscular Atrophy Market

12.2 Spinal Muscular Atrophy Patients

12.3 Spinal Muscular Atrophy Treated Patient Numbers

13. DRUGS SALES – SPINAL MUSCULAR ATROPHY

13.1 Spinraza

13.2 AVXS-101

13.3 CK2127107

13.4 RG7916

13.5 Olesoxime

13.6 LMI070

14. SPINAL MUSCULAR ATROPHY STUDY STATUS ANALYSIS

14.1 Spinal Muscular Atrophy Clinical Study

14.2 Spinal Muscular Atrophy Drugs Development Pipeline

15. GROWTH DRIVERS

- 15.1 Increasing Funding for Research & Development
- 15.2 Biogen Access Programs

16. CHALLENGES

- 16.1 High Treatment Cost
- 16.2 Common Side Effects

17. BIOGEN INC.

- 17.1 Business Overview
- 17.2 Initiatives/Strategies
 - 17.2.1 Point
 - 17.2.2 Point
 - 17.2.3 Point
- 17.3 Financial Insight

18. NOVARTIS AG

- 18.1 Business Overview
- 18.2 Initiatives/Strategies
 - 18.2.1 Point
 - 18.2.2 Point
- 18.3 Financial Insight

19. ROCHE HOLDING AG

- 19.1 Business Overview
- 19.2 Initiatives/Strategies
 - 19.2.1 Point
 - 19.2.2 Point
- 19.3 Financial Insight

20. CYTOKINETICS, INC.

- 20.1 Business Overview

20.2 Initiatives/Strategies

20.2.1 Point

20.2.2 Point

20.3 Financial Insight

List Of Figures

LIST OF FIGURES

Figure 2.1: Global – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 2.2: Global – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 2.3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 3.1: Global – Current & Forecast for Spinal Muscular Atrophy Market Share (Percent), 2017 – 2026

Figure 3.2: Global – Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 – 2026

Figure 3.3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients Share (Percent), 2017 – 2026

Figure 4.1: United States – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 4.2: United States – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 4.3: United States – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 5.1: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 5.2: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 5.3: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 6.1: Germany – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 6.2: Germany – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 6.3: Germany – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 7.1: Italy – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 7.2: Italy – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 7.3: Italy – Current & Forecast for Spinal Muscular Atrophy Treated Patients

(Number), 2017 – 2026

Figure 8.1: France – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 8.2: France – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 8.3: France – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 9.1: Spain – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 9.2: Spain – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 9.3: Spain – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 10.1: Japan – Current & Forecast for Spinal Muscular Atrophy Market (Million US\$), 2017 – 2026

Figure 10.2: Japan – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026

Figure 10.3: Japan – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 11.1: Global – Current & Forecast for Spinraza Sales (Million US\$), 2017 – 2026

Figure 11.2: Global – Current & Forecast for AVXS-101 Sales (Million US\$), 2017 – 2026

Figure 11.3: Global – Current & Forecast for CK212710 Sales (Million US\$), 2022 – 2026

Figure 11.4: Global – Current & Forecast for RG7916 Sales (Million US\$), 2024 – 2026

Figure 11.5: Global – Current & Forecast for LMI070 Sales (Million US\$), 2021 – 2026

Figure 12.1: Spinal Muscular Atrophy Drugs Development Pipeline, September 2018

Figure 15.1: Biogen – Global Sales (Million US\$), 2013 – 2017

Figure 15.2: Biogen – Forecast for Global Sales (Million US\$), 2018 – 2026

Figure 16.1: Novartis – Global Sales (Million US\$), 2013 – 2017

Figure 16.2: Novartis – Forecast for Global Sales (Million US\$), 2018 – 2026

Figure 17.1: Roche – Global Sales (Million US\$), 2013 – 2017

Figure 17.2: Roche – Forecast for Global Sales (Million US\$), 2018 – 2026

Figure 18.1: Cytokinetics – Global Sales (Thousand US\$), 2013 – 2017

List Of Tables

LIST OF TABLES

Table 12 1: Global – Spinal Muscular Atrophy Clinical Study Status, 2018

I would like to order

Product name: Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)

Product link: <https://marketpublishers.com/r/S8A9375EE78EN.html>

Price: US\$ 2,190.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S8A9375EE78EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970